Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 862-871

  Huang, Wei ^a   Wu, Qun dan ^a   Zhang, Min ^a   Kong, Ying li ^a   Cao, Pin rong ^a   Zheng, Wei ^a,b   Xu, Jian hua ^a,c   Ye, Min ^a,c  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b FUJIAN INSTITUTE OF MICROBIOLOGY   (China)

^c Fuijan Provincial Key Laboratory of Natural Medicine Pharmacology   (China)

Author keywords

FW 04 806; HER2; HER2 positive breast cancer; HER3

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; FW 04 806; HEAT SHOCK PROTEIN 90 INHIBITOR; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAS PROTEIN; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CONGLOBATIN; ERBB2 PROTEIN, HUMAN; HEAT SHOCK PROTEIN 90; MESSENGER RNA; OXAZOLE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; IN VITRO STUDY; IN VIVO STUDY; MITOSIS INHIBITION; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; ENZYME IMMUNOASSAY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED BALB C; MICE, NUDE; OXAZOLES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919480571     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.10.040     Document Type: Article

References (50)

1. Saini K.S., Azim H.A., Metzger-Filho O., Loi S., Sotiriou C., de Azambuja E., et al. Beyond trastuzumab: new treatment options for HER2-positive breast cancer. Breast 2011, 20(Suppl. 3):S20-S27.
2. Tzahar E., Waterman H., Chen X., Levkowitz G., Karunagaran D., Lavi S., et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell. Biol 1996, 16(10):5276-5287.
3. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235(4785):177-182.
4. Zell J.A., Tsang W.Y., Taylor T.H., Mehta R.S., Anton-Culver H. Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry. Breast Cancer Res 2009, 11(1):R9.
5. Dawood S., Broglio K., Buzdar A.U., Hortobagyi G.N., Giordano S.H. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J. Clin. Oncol 2010, 28(1):92-98.
6. Zardavas D., Cameron D., Krop I., Piccart M. Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer. Am. Soc. Clin. Oncol. Educ. Book 2013, 10.1200/EdBook_AM.2013.33.e2.
7. Gennari R., Menard S., Fagnoni F., Ponchio L., Scelsi M., Tagliabue E., et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin. Cancer Res 2004, 10(17):5650-5655.
8. Kopper L. Lapatinib: a sword with two edges. Pathol. Oncol. Res 2008, 14(1):1-8.
9. MacFarlane R.J., Gelmon K.A. Lapatinib for breast cancer: a review of the current literature. Expert Opin. Drug Saf 2011, 10(1):109-121.
10. Agus D.B., Akita R.W., Fox W.D., Lewis G.D., Higgins B., Pisacane P.I., et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002, 2(2):127-137.
11. Isakoff S.J., Baselga J. Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol 2011, 29(4):351-354.
12. Yap T.A., Vidal L., Adam J., Stephens P., Spicer J., Shaw H., et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J. Clin. Oncol 2010, 28(25):3965-3972.
13. Wong K.K., Fracasso P.M., Bukowski R.M., Lynch T.J., Munster P.N., Shapiro G.I., et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin. Cancer Res 2009, 15(7):2552-2558.
14. Baselga J., Swain S.M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 2009, 9(7):463-475.
15. Citri A., Kochupurakkal B.S., Yarden Y. The Achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 2004, 3(1):51-60.
16. Solit D.B., Zheng F.F., Drobnjak M., Munster P.N., Higgins B., Verbel D., et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res 2002, 8(5):986-993.
17. Jensen M.R., Schoepfer J., Radimerski T., Massey A., Guy C.T., Brueggen J., et al. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 2008, 10(2):R33.
18. Zsebik B., Citri A., Isola J., Yarden Y., Szollosi J., Vereb G. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunol. Lett 2006, 104(1-2):146-155.
19. Modi S., Stopeck A.T., Gordon M.S., Mendelson D., Solit D.B., Bagatell R., et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J. Clin. Oncol 2007, 25(34):5410-5417.
20. Baselga J., Bradbury I., Eidtmann H., Di Cosimo S., de Azambuja E., Aura C., et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012, 379(9816):633-640.
21. Leow C.C., Chesebrough J., Coffman K.T., Fazenbaker C.A., Gooya J., Weng D., et al. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib. Mol. Cancer Ther 2009, 8(8):2131-2141.
22. Oude Munnink T.H., de Vries E.G., Vedelaar S.R., Timmer-Bosscha H., Schroder C.P., Brouwers A.H., et al. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts. Mol. Pharm 2012, 9(11):2995-3002.
23. Huang W., Ye M., Zhang L.R., Wu Q.D., Zhang M., Xu J.H., et al. FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation. Mol. Cancer 2014, 13(1):150.
24. Vazquez-Martin A., Oliveras-Ferraros C., Cufi S., Del Barco S., Martin-Castillo B., Menendez J.A. Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth. J. Cell. Physiol 2011, 226(1):52-57.
25. Scaltriti M., Verma C., Guzman M., Jimenez J., Parra J.L., Pedersen K., et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 2009, 28(6):803-814.
26. Chen Y.J., Chi C.W., Su W.C., Huang H.L. Lapatinib induces autophagic cell death and inhibits growth of human hepatocellular carcinoma. Oncotarget 2014, 5(13):4845-4854.
27. Li Y.M., Pan Y., Wei Y., Cheng X., Zhou B.P., Tan M., et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 2004, 6(5):459-469.
28. Singh A., Ye M., Bucur O., Zhu S., Tanya Santos M., Rabinovitz I., et al. Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT. Mol. Biol. Cell 2010, 21(6):1140-1152.
29. Huang W., Jia W., Fu H., Cheng H., Xu J., Jiang H., et al. Structure identification and anti-tumor activity research of FW-04-806. Zhongguo Kang Sheng Su Za Zhi 2011, 36(7):502-508.
30. Chen H., Jia W., Huang W., Fu H., Jiang H., Wei Z. Optimization of fermentation conditions for FW-04-806, a macrolide dilactone compound with two oxazole ring. Zhongguo Kang Sheng Su Za Zhi 2012, 37(1):45-49.
31. Burgering B.M. A brief introduction to FOXOlogy. Oncogene 2008, 27(16):2258-2262.
32. Calnan D.R., Brunet A. The FoxO code. Oncogene 2008, 27(16):2276-2288.
33. Arden K.C. FOXO animal models reveal a variety of diverse roles for FOXO transcription factors. Oncogene 2008, 27(16):2345-2350.
34. Fernandez de Mattos S., Villalonga P., Clardy J., Lam E.W. FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells. Mol. Cancer Ther 2008, 7(10):3237-3246.
35. Hui R.C., Gomes A.R., Constantinidou D., Costa J.R., Karadedou C.T., Fernandez de Mattos S., et al. The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expression. Mol. Cell. Biol 2008, 28(19):5886-5898.
36. McGovern U.B., Francis R.E., Peck B., Guest S.K., Wang J., Myatt S.S., et al. Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Mol. Cancer Ther 2009, 8(3):582-591.
37. Chou T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010, 70(2):440-446.
38. Garrett J.T., Olivares M.G., Rinehart C., Granja-Ingram N.D., Sanchez V., Chakrabarty A., et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc. Natl. Acad. Sci. U.S.A. 2011, 108(12):5021-5026.
39. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev 2006, 58(3):621-681.
40. Stern D.F. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J. Mammary Gland Biol. Neoplasia 2008, 13(2):215-223.
41. Garrett J.T., Sutton C.R., Kuba M.G., Cook R.S., Arteaga C.L. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Clin. Cancer Res 2013, 19(3):610-619.
42. Nagumo Y., Faratian D., Mullen P., Harrison D.J., Hasmann M., Langdon S.P. Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity. Mol. Cancer Res 2009, 7(9):1563-1571.
43. Narayan M., Wilken J.A., Harris L.N., Baron A.T., Kimbler K.D., Maihle N.J. Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. Cancer Res 2009, 69(6):2191-2194.
44. Holbro T., Beerli R.R., Maurer F., Koziczak M., Barbas C.F., Hynes N.E. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 2003, 100(15):8933-8938.
45. Lee-Hoeflich S.T., Crocker L., Yao E., Pham T., Munroe X., Hoeflich K.P., et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008, 68(14):5878-5887.
46. Ding J., Wong T.Y. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr. Diab. Rep 2012, 12(4):346-354.
47. Chandarlapaty S., Sawai A., Scaltriti M., Rodrik-Outmezguine V., Grbovic-Huezo O., Serra V., et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011, 19(1):58-71.
48. Chakrabarty A., Sanchez V., Kuba M.G., Rinehart C., Arteaga C.L. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2012, 109(8):2718-2723.
49. Krol J., Francis R.E., Albergaria A., Sunters A., Polychronis A., Coombes R.C., et al. The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells. Mol. Cancer Ther 2007, 6(12 Pt 1):3169-3179.
50. Westley J.W., Liu C.M., Evans R.H., Blount J.F. Conglobatin, a novel macrolide dilactone from Streptomyces conglobatus ATCC 31005. J. Antibiot. (Tokyo) 1979, 32(9):874-877.